arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Ocugen, Inc.

OCGN Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$0.74
▼ -9.7% Today
as of Oct 23, 15:05 ET
Last 30 days -30.39% Sep 14 → Oct 23
$0.71 $0.81 $0.91 $1.02 $1.12 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$0.80
High
$0.83
Low
$0.79
Volume
$7M
Avg Vol
$6M
Mkt Cap
$339M
P/E (TTM)
—
Beta
—
52w High
$2.73
52w Low
$0.78
Div Yield
—
Shares Out
$339M

Recent Press Releases & News last 60 days · 15 items

Oct 22 · 11:00 PR GlobeNewswire
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Oct 14 · 11:13 MT Newswires
Ocugen Signs MENA Licensing Deal for OCU400
Oct 14 · 10:30 PR GlobeNewswire
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
▸ Show all 15 press releases & news Free account →

OCGN earnings at a glance

Ocugen, Inc. (OCGN) is scheduled to report earnings on Wednesday, November 4, 2026 — in 12 days. Analysts expect earnings per share of -$0.06, compared with -$0.07 in the same quarter last year (+14%). The options market is pricing a move of about ±15.2% after the report, a range of roughly $0.63 to $0.85 from today's $0.74. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±3.5% on average; after the most recent report on Aug 6, 2026 it moved -3.1%. That means options currently expect more movement than OCGN has typically delivered. OCGN beat the consensus EPS estimate in 2 of its last 6 reported quarters. Implied volatility is currently 129%. The share price of $0.74 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.78
$2.73
0% of range
Avg surprise (last 6)
-7.2%
Avg reaction (last 6)
-0.1%
33% positive
Latest IV / EM
129%
EM ±15.2% · $1 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.60$-0.33$-0.07$0.20$0.46 Actual $-0.08Actual $-0.10Actual $-0.05Actual $-0.04Actual $-0.05Est $-0.06Actual $-0.05Est $-0.06Actual $-0.07Est $-0.06Actual $-0.06Est $-0.06Actual $-0.06Est $-0.05Actual $-0.07Est $-0.05 MarJunMarJunMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-25M$-18M$-12M$-5M$2M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Aug 6, 2026Jun/2026 $-0.07 $-0.05 -40.0% 0.0% -3.1% earnings
Tue May 5, 2026Mar/2026 $-0.06 $-0.05 -20.0% -20.0% +4.9% earnings
Wed Mar 4, 20268K 2026-03-04 $-0.06 $-0.06 0.0% — +5.4% earnings
Wed Nov 5, 2025Sep/2025 $-0.07 $-0.06 -16.7% — -1.4% earnings
Fri Aug 1, 2025Jun/2025 $-0.05 $-0.06 +16.7% — -3.5% earnings
Fri May 9, 2025Mar/2025 $-0.05 $-0.06 +16.7% — -2.8% earnings
Sun Jun 30, 2024Jun 2024 $-0.04 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.05 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.10 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.08 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Nov 4, 2026Sep/2026OTHER -$0.06-$0.07 +14.3%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1M$2M—$2M$1M$1M—$1M
Cost of revenue————————
Gross profit————————
Operating income$-16M$-18M—$-18M$-14M$-15M—$-13M
Net income$-25M$-19M—$-20M$-15M$-15M—$-13M
EPS (diluted)$-0.07$-0.06——$-0.05$-0.05——

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$100M$32M$19M$33M$27M$38M—$39M
Inventory————————
Total current assets$107M$39M$24M$38M$33M$44M$62M$41M
Total assets$124M$57M$44M$58M$54M$64M$82M$62M
Long-term debt$2M$24M$28M$28M$28M$28M$27M$2M
Total liabilities$141M$51M$56M$54M$51M$49M$53M$21M
Total equity$-17M$6M$-12M$4M$3M$16M$30M$41M

Implied volatility — last 90 days

69%309%549%789%1029% Jun 07 — IV 254% · EM ±35.2%Jun 11 — IV 371% · EM ±41.0%Jun 17 — IV 1029% · EM ±43.0%Jun 19 — IV 292% · EM ±64.5%Jun 22 — IV 120% · EM ±25.0%Jun 23 — IV 105% · EM ±21.6%Jun 24 — IV 187% · EM ±37.5%Jun 25 — IV 112% · EM ±21.9%Jun 26 — IV 87% · EM ±16.7%Jun 29 — IV 102% · EM ±18.1%Jun 30 — IV 113% · EM ±19.5%Jul 01 — IV 281% · EM ±47.0%Jul 02 — IV 92% · EM ±14.9%Jul 03 — IV 95% · EM ±14.9%Jul 06 — IV 108% · EM ±15.0%Jul 07 — IV 101% · EM ±13.3%Jul 08 — IV 93% · EM ±11.7%Jul 09 — IV 234% · EM ±27.6%Jul 13 — IV 253% · EM ±21.1%Jul 14 — IV 331% · EM ±24.0%Jul 15 — IV 295% · EM ±17.4%Jul 16 — IV 437% · EM ±18.2%Jul 20 — IV 411% · EM ±97.0%Jul 21 — IV 179% · EM ±41.7%Jul 22 — IV 109% · EM ±25.0%Jul 23 — IV 175% · EM ±39.4%Jul 27 — IV 226% · EM ±47.2%Jul 28 — IV 355% · EM ±72.6%Jul 30 — IV 182% · EM ±35.7%Aug 03 — IV 167% · EM ±29.6%Aug 04 — IV 278% · EM ±48.0%Aug 05 — IV 187% · EM ±31.2%Aug 07 — IV 227% · EM ±35.4%Aug 10 — IV 276% · EM ±38.2%Aug 12 — IV 171% · EM ±21.4%Aug 13 — IV 220% · EM ±26.0%Aug 17 — IV 218% · EM ±18.2%Aug 18 — IV 619% · EM ±44.8%Aug 24 — IV 70% · EM ±14.6%Aug 25 — IV 87% · EM ±17.9%Aug 26 — IV 124% · EM ±24.8%Aug 27 — IV 429% · EM ±83.9%Aug 28 — IV 158% · EM ±30.3%Aug 31 — IV 194% · EM ±34.4%Sep 01 — IV 240% · EM ±41.4%Sep 04 — IV 235% · EM ±36.8%Sep 07 — IV 265% · EM ±36.8%Sep 08 — IV 325% · EM ±42.9%Sep 09 — IV 220% · EM ±27.5%Sep 10 — IV 244% · EM ±28.8%Sep 11 — IV 132% · EM ±14.6%Sep 14 — IV 280% · EM ±23.4%Sep 21 — IV 103% · EM ±21.4%Sep 22 — IV 130% · EM ±26.7%Sep 23 — IV 74% · EM ±14.9%Sep 24 — IV 128% · EM ±25.0%Sep 25 — IV 89% · EM ±17.0%Sep 28 — IV 110% · EM ±19.4%Sep 29 — IV 133% · EM ±22.9%Sep 30 — IV 143% · EM ±23.8%Oct 01 — IV 107% · EM ±17.3%Oct 02 — IV 157% · EM ±24.5%Oct 06 — IV 107% · EM ±14.2%Oct 07 — IV 117% · EM ±14.7%Oct 08 — IV 129% · EM ±15.2%

Sector peers

ARTV
Artiva Biotherapeutics, Inc.
$332M $6.08-6.3%
CCCC
C4 Therapeutics, Inc.
$347M $3.06-3.3%
CABA
Cabaletta Bio, Inc.
$320M $1.44-6.5%
FENC
Fennec Pharmaceuticals Inc.
$365M $10.14-2.3%
AGEN
Agenus Inc.
$376M $6.35-0.8%
AVXL
Anavex Life Sciences Corp.
$300M $1.30-4.0%

OCGN earnings FAQ

When is OCGN's next earnings date?

Ocugen, Inc. is expected to report on November 4, 2026.

What is OCGN's expected move for earnings?

Options currently price a move of about ±15.2%, or $0.11 per share either way from $0.74.

How does OCGN stock usually react to earnings?

Across the last 6 reports the average next-day move was ±3.5%, up 2 times and down 4 times.

What EPS are analysts expecting from Ocugen, Inc.?

The consensus estimate is -$0.06 per share, versus -$0.07 a year ago.

What is OCGN's implied volatility?

OCGN's at-the-money implied volatility is about 129% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in